

Single puncture approach guided by transesophageal echocardiography for atrial fibrillation ablation in a patient with prior percutaneous septal closure: case report

Mário Oliveira ()^{1,2,3}*, Lidia Sousa^{1,3}, Ana Trindade¹, and Nogueira da Silva¹

¹Heart Center, Hospital CUF Tejo, Lisbon, Portugal; ²Faculty of Medicine of Lisbon, CCUL, Lisbon, Portugal; and ³Hospital Santa Marta, CHULC, Lisbon, Portugal

Received 19 March 2022; first decision 11 May 2022; accepted 24 March 2023; online publish-ahead-of-print 12 April 2023

Background	Atrial septal defect (ASD) is associated with a risk of developing atrial fibrillation (AF) higher than in the general population, even after percutaneous or surgical septal closure. Catheter ablation is an effective treatment strategy for preventing recurrences and reducing the AF burden. However, electrophysiologists are faced with technical difficulties and the risk of complications with the left atrium access in patients with prior ASD percutaneous closure.
Case summary	We report a case of a patient with highly symptomatic paroxysmal AF, with an ASD, closed percutaneously many years before, who underwent a successful catheter AF ablation, using a single transeptal (TSP) approach guided by transesophageal echocardiography (TEE).
Discussion	In patients with ASD and an occluder device implanted, there is a potential risk for septal tear during the TSP passage, device dis- lodgement, or thrombus formation on the device. Atrial fibrillation ablation in this subset of patients has often been protracted and scarcely reported. TEE and intra-cardiac echocardiography have been increasingly used for interventional procedure guidance dur- ing AF ablation. As described here, AF ablation using a simplified single TSP guided by TEE is feasible, safe, and effective after device ASD closure.
Keywords	Atrial septal defect • Percutaneous device closure • Atrial fibrillation ablation • Case report
ESC Curriculum	9.7 Adult congenital heart disease • 5.3 Atrial fibrillation • 2.2 Echocardiography

Learning Points

- AF ablation (PVI) performed using a simplified single transeptal puncture after atrial septal closure, even with a large closure device
- The usefulness of real-time TEE imaging in catheter AF ablation after atrial septal defect closure
- Safety and feasibility of catheter AF ablation after percutaneous device atrial septal defect closure
- Emphasis on the fact that there is no reason to delay AF ablation decision in patients with prior percutaneous septal closure

^{*} Corresponding author. Tel: 351962518851, Email: m.martinsoliveira@gmail.com

Handling Editor: Filippo Puricellio

Peer-Reviewers: Vincenzo Nuzzi; Christoph Sinning

Compliance Editor: Lavanya Athithan

Supplementary Material Editor: Michael Waight

[©] The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Introduction

Atrial septal defect (ASD) is associated with a prevalence of atrial fibrillation (AF) higher than in the general population, a risk that persists after percutaneous or surgical septal closure.¹ Catheter ablation is an effective treatment strategy for preventing recurrences and reducing the AF burden.² However, electrophysiologists are faced with technical difficulties and the risk of complications with the left atrium (LA) access in patients with prior ASD percutaneous closure. This challenge usually protracts the option of AF ablation in the population with an implanted ASD closure device. We report a case of a patient with highly symptomatic paroxysmal AF, with an ASD, closed percutaneously many years before, submitted to a successful AF ablation using a single transeptal approach.


Timeline

the anatomical map of two right pulmonary veins (PV) and two left PV, and excluded intra-cardiac thrombus (*Figure 1*).

AF ablation

The procedure was performed under general anaesthesia, with propofol and fentanyl for induction, followed by neuromuscular blocking with rocuronium and by laryngeal mask. Right femoral vein access was obtained to place a 6 Fr decapolar catheter into the coronary sinus.

TEE (TEE) was used to guide transseptal puncture (TSP). A small portion of the native atrial septum immediately posteroinferior to the Amplatzer occluder device was identified as the site to cross to the LA (*Figure 2*). A single TSP was done, and an 8.5 Fr deflectable bidirectional sheath (Agilis NxT, St. Jude Medical) was gently positioned toward the LA, with exchanges of a circular catheter (Advisor[™] FL,



Case description

A 55-year-old female with a history of a previous successful ASD closure with an Amplatzer 26 mm occluder device (St. Jude Medical) 10 years before presented recurrent episodes of chest discomfort and rapid palpitations for the last three years due to paroxysmal AF. She maintained frequent symptoms despite medication with betablocker combined with propafenone, and amiodarone was interrupted due to ineffectiveness and hypothyroidism. She presented with well-controlled hypertension (medicated with 5 mg perindopril QD), had a CHA₂DS₂-Vasc score of 2, and was anticoagulated with apixaban. On physical examination, S1 and S2 on cardiac auscultation were rhythmic, with no murmur; blood pressure was 135/75 mmHg, pulmonary auscultation was normal, and there was no oedema of the lower limbs.

Transthoracic echocardiogram showed an occluder device wellpositioned, slight LA dilation (38 mL/m^2), and a left ventricle ejection fraction of 60%, without valvular abnormalities. The cardiac computed tomography visualized the device position, provided information for Abbott) and the ablation catheter (Tacticath ${\ensuremath{^{\rm TM}}}$, Abbott) made through the same sheath.

Heparin administration reached an ACT level of >300 s during the procedure.

Left atrium geometry was collected with the circular catheter using the Ensite Velocity electroanatomic mapping system (Abbott) (*Figure 3*).

The ablation strategy consisted of PV isolation using antral circumferential radiofrequency (RF) lesions (30-35 W power). The endpoint was the elimination of the local bipolar electrograms or attaining a forcetime integral >400 g/s. A lower power (20-25 W) and lower duration settings were used for ablation on the posterior LA wall adjacent to the PV. Real-time contact force was continuously monitored in order to achieve a mean contact force of 10 g during RF application.

The patient was admitted to the laboratory in AF, having converted to sinus rhythm during isolation of the right superior PV (*Figure 4*). Elimination of PV potentials with isolation of all PV was obtained without procedural complications. Apixaban was continued on the same day. During a period of 12-month follow-up, there were no palpitations, and the event recordings were free from AF.





Figure 1 Reconstruction images of computed tomographic angiography of the left atrium showing the location of the Amplatzer septal occluder device (white arrow). LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein.



Figure 2 Sequence of transesophageal echocardiography images showing the Amplatzer device location (*A*, unbroken arrow), the site to perform the transeptal puncture (*A*, dashed arrow), and the Brockenbrough needle progression (Medtronic, Minneapolis, MN) (*B*, *C*, and *D*).








Figure 4 Conversion of atrial fibrillation to sinus rhythm during radiofrequency applications in the antrum of the right superior pulmonary vein isolation documented by electrocardiogram (ECG) (leads I and II) and intra-cardiac electrograms from a decapolar catheter positioned into the coronary sinus. AF, atrial fibrillation; SR, sinus rhythm.

Discussion

TSP catheterization is routinely performed in AF ablation, either with a single or double puncture.³ It is an important step in the procedure of PV isolation, with a low risk of complications, when undertaken by

experienced operators. In the growing population of patients with atrial septal occluders, due to atrial septal defects or patent foramen ovale, AF is a common finding, but TSP puncture and sheath manipulation became challenging, particularly in identifying an ideal space outside the implantable device to perform a safe puncture. In these patients, there is a potential risk for septal tear during the transeptal passage, device dislodgement, or thrombus formation on the device. Because of the difficult LA access and risk of complications, AF ablation in this subset of patients has been often been protracted and scarcely reported.

TEE and intra-cardiac echocardiography (ICE) have been increasingly used for detailed anatomical assessment and interventional procedure guidance for atrial septal closure and AF ablation. In a recent systematic review using ICE guidance, there were no acute procedural related complications, and the pooled incidence of long-term freedom from AF was 77.7%.⁴ Therefore, the decision for undergoing AF ablation should not be delayed in patients with prior percutaneous septal closure. In this case report, with a 26 mm occluder device implanted many years before, we selected TEE, considering the expertise of one of the operators and the higher cost of ICE catheters. As described here, AF ablation using a simplified single TSP guided by TEE is feasible, safe, and effective in patients after device ASD closure, although this is a complex procedure that should be performed by experienced operators.

Lead author biography



Professor at Lisbon Faculty of Medicine and head of the Electrophysiology Unit at Hospital Santa Marta and of the Heart Center, at Hospital CUF Tejo, in Lisbon. PhD thesis—Molecular and Electrophysiological Basis of Autonomic Nervous System Influence in the Genesis and Maintenance of Paroxysmal AF. Major research—ANS and arrhythmogenesis. Past vice-president of the Portuguese Society of Cardiology, past-president of the Portuguese Association of Arrhythmology, Pacing

and Electrophysiology, and member of the EHRA National Cardiac Societies Committee. Associate Editor of the Portuguese Journal of Cardiology and reviewer of international journals. He has delivered >300 lectures and authored 150 papers, >500 abstracts, and 40 scientific prizes.

Supplementary material

Supplementary material is available at European Heart Journal – Case Reports.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm that written informed consent for submission and publication of this case report, including the images and associated text, has been obtained from the patient in line with COPE guidance.

Conflict of interest: None declared.

Funding: None declared.

Data availability

The data underlying this article are available in the article and in its online supplementary material.

References

- Evertz R, Reinders M, Houck C, Ten Cate T, Duijnhouwer AL, Beukema R, et al. Atrial fibrillation in patients with an atrial septal defect in a single center cohort during a long clinical follow-up: its association with closure and outcome of therapy. Open Heart 2020;7:e001298.
- 2. Amuthan R, Curtis A. What clinical trials of ablation for atrial fibrillation tell us—and what they do not. *Heart Rhythm O2* 2021;**2**:174–186.
- Stauber A, Kornej J, Sepehri A, Dinov B, Bacevicius J, Dagres N, et al. Impact of single versus double transseptal puncture on outcome and complications in pulmonary vein isolation procedures. Cardiol J 2021;28:671–677.
- Garg J, Shah K, Turagam MK, Janagam P, Natale A, Lakkireddy D, et al. Safety and efficacy of catheter ablation for atrial fibrillation in patients with percutaneous atrial septal closure device: Electrophysiology Collaborative Consortium for Meta-analysis—ELECTRAM Investigators. J Cardiovasc Electrophysiol 2020;31:2328–2334.